Literature DB >> 24298364

Tissue regeneration and stem cell distribution in adriamycin induced glomerulopathy.

Maha Baligh Zickri1, Marwa Mohamed Abdel Fattah, Hala Gabr Metwally.   

Abstract

BACKGROUND AND OBJECTIVES: Glomerulosclerosis develops secondary to various kidney diseases. It was postulated that adriamycin (ADR) induce chronic glomerulopathy. Treatment combinations for one year did not significantly modify renal function in resistant focal segmental glomerulosclerosis (FSGS). Recurrence of FSGS after renal transplantation impacts long-term graft survival and limits access to transplantation. The present study aimed at investigating the relation between the possible therapeutic effect of human mesenchymal stem cells (HMSCs), isolated from cord blood on glomerular damage and their distribution by using ADR induced nephrotoxicity as a model in albino rat. METHODS AND
RESULTS: Thirty three male albino rats were divided into control group, ADR group where rats were given single intraperitoneal (IP) injection of 5 mg/kg adriamycin. The rats were sacrificed 10, 20 and 30 days following confirmation of glomerular injury. In stem cell therapy group, rats were injected with HMSCs following confirmation of renal injury and sacrificed 10, 20 and 30 days after HMSCs therapy. Kidney sections were exposed to histological, histochemical, immunohistochemical, morphometric and serological studies. In response to SC therapy multiple Malpighian corpuscles (MC) appeared with patent Bowman's space (Bs) 10 and 20 days following therapy. One month following therapy no remarkable shrunken glomeruli were evident. Glomerular area and serum creatinine were significantly different in ADR group in comparison to control and SC therapy groups.
CONCLUSIONS: ADR induced glomerulosclerosis regressed in response to cord blood HMSC therapy. A reciprocal relation was recorded between the extent of renal regeneration and the distribution of undifferentiated mesenchymal stem cells.

Entities:  

Keywords:  Adriamycin; Cord blood; Glomerulosclerosis; Mesenchymal stem cells

Year:  2012        PMID: 24298364      PMCID: PMC3840995          DOI: 10.15283/ijsc.2012.5.2.115

Source DB:  PubMed          Journal:  Int J Stem Cells        ISSN: 2005-3606            Impact factor:   2.500


  31 in total

1.  Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis.

Authors:  Uta Kunter; Song Rong; Zivka Djuric; Peter Boor; Gerhard Müller-Newen; Donghai Yu; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2006-06-21       Impact factor: 10.121

Review 2.  Mediation and moderation of treatment effects in randomised controlled trials of complex interventions.

Authors:  Richard Emsley; Graham Dunn; Ian R White
Journal:  Stat Methods Med Res       Date:  2009-07-16       Impact factor: 3.021

3.  Does injection of metanephric mesenchymal cells improve renal function in rats?

Authors:  Yu-qing Jiao; Zhu-wen Yi; Xiao-jie He; Xi-hong Liu; Qing-nan He; Dan-lin Huang
Journal:  Saudi J Kidney Dis Transpl       Date:  2011-05

4.  Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity.

Authors:  Jinzhou Zhu; Jing Zhang; Di Xiang; Zhonghui Zhang; Lin Zhang; Mingyuan Wu; Shunying Zhu; Ruiyan Zhang; Wei Han
Journal:  Eur J Pharmacol       Date:  2010-06-30       Impact factor: 4.432

5.  Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis.

Authors:  A Segarra Medrano; J Vila Presas; L Pou Clavé; J Majó Masferrer; J Camps Doménech
Journal:  Nefrologia       Date:  2011-03-15       Impact factor: 2.033

6.  Ex vivo-expanded bone marrow stem cells home to the liver and ameliorate functional recovery in a mouse model of acute hepatic injury.

Authors:  Shi-Zhu Jin; Bing-Rong Liu; Jun Xu; Fu-Lai Gao; Zong-Jing Hu; Xin-Hong Wang; Feng-Hua Pei; Yu Hong; Hong-Yan Hu; Ming-Zi Han
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2012-02

7.  Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin.

Authors:  Jean-Charles Gautier; Björn Riefke; Jakob Walter; Petra Kurth; Lou Mylecraine; Valérie Guilpin; Norman Barlow; Thierry Gury; David Hoffman; Daniela Ennulat; Kerstin Schuster; Ernie Harpur; Syril Pettit
Journal:  Toxicol Pathol       Date:  2010-08-17       Impact factor: 1.902

8.  Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy.

Authors:  S C W Tang; J C K Leung; L Y Y Chan; A A Eddy; K N Lai
Journal:  Kidney Int       Date:  2007-11-21       Impact factor: 10.612

9.  Experimental diabetic nephropathy can be prevented by propolis: Effect on metabolic disturbances and renal oxidative parameters.

Authors:  Osama M Abo-Salem; Rawhia H El-Edel; Gamal Eldin I Harisa; Nermin El-Halawany; Mabrouk M Ghonaim
Journal:  Pak J Pharm Sci       Date:  2009-04       Impact factor: 0.684

10.  Polyphenolic fraction of Algerian propolis protects rat kidney against acute oxidative stress induced by doxorubicin.

Authors:  K Boutabet; W Kebsa; M Alyane; M Lahouel
Journal:  Indian J Nephrol       Date:  2011-04
View more
  1 in total

1.  Original Research: Potential of urinary nephrin as a biomarker reflecting podocyte dysfunction in various kidney disease models.

Authors:  Yusuke Wada; Masaki Abe; Hiroshi Moritani; Hikaru Mitori; Mitsuhiro Kondo; Keiko Tanaka-Amino; Megumi Eguchi; Akira Imasato; Yutaka Inoki; Hiroshi Kajiyama; Toshihide Mimura; Yuichi Tomura
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.